Clinical indications for, and the future of, circulating tumor cells
- 1 February 2018
- journal article
- review article
- Published by Elsevier BV in Advanced Drug Delivery Reviews
- Vol. 125, 143-150
- https://doi.org/10.1016/j.addr.2018.04.002
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (U54CA198999)
- Carolina Center of Cancer Nanotechnology Excellence
- Nano Approaches to Modulate Host Cell Response for Cancer Therapy
This publication has 99 references indexed in Scilit:
- The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept StudyPLOS ONE, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancerGynecologic Oncology, 2011
- Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate CancerClinical Genitourinary Cancer, 2011
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Vimentin in cancer and its potential as a molecular target for cancer therapyCellular and Molecular Life Sciences, 2011
- Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic reviewBritish Journal of Cancer, 2010
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004